It seems that the search for youthful glow has taken a drastic turn.

A company by the name of Ambrosia is now offering blood transfusions for those looking to add years to their life and a little pep in their step. Based in Monterey California launching a clinical trial to inject the blood of young people into just about anyone aged 35 and up—if they’re willing to pay $8,000.

Young-to-old blood transfusions hit the limelight in 2014 when Harvard Stem Cell Institute researcher Amy Wagers discovered that the blood of young mice improved muscle, heart, and brain function in older mice. Scientists sewed the skin of two mice together, allowing their circulatory systems to merge. The surgery, called parabiosis, was first performed in the 1860s but has seen a resurgence of interest following Wagers’s study.

Another company called Alkahest has been conducting a clinical trial with young blood infused into patients with probable Alzheimer’s. Its results are expected out by the end of the year.

Throughout history, there have been those who believed that the blood of the young could keep them alive long past their “natural time.”  Interest in this theory is not limited to Hollywood elite or the wealthy of our day but goes back to Pope Innocent VIII back in the 1400's who thought that the blood of a 10-year-old boy would keep him from his death. Although he did not get a transfusion in the way we know of today but rather drank the blood hoping it would filter into his system that way.

While these theories are now going to clinical trials the elite of Silicon Valley are flocking to it in hopes to maintain their quality of life.

PayPal co-founder and Facebook investor Peter Thiel recently revealed in an interview with  Inc. he finds parabiosis “really interesting” and said his curiosity leans more toward his own personal health rather than a potential business investment. This is not the first time Thiel has shown an interest in combatting aging.

As the life expectancy of people increases they are looking to not only live longer but live younger and they will attempt it by any means necessary. The Ambrosia trial is set to give 600 participants four weekly rounds of blood infusions from patients who range in age from 16-25.

While the scientific data has not been validated the theory has been practiced for centuries and if proven the implications of the data would be life changing for many people.

Guess we will have to wait and see if it works.

Sources: Science Mag, Scientific American, Technology Review